PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

Summary

This is a phase II study assessing response rate to PF-06463922 in patients with ROS1 translocation resistant to previous crizotinib therapy. Eligible patients will be treated with the study drug until disease progression, unacceptable toxicity or patient refusal. Disease assessment will be performed every 8 weeks according to RECIST criteria.

Timeline

Start

2017-06-13

Primary completion

2022-06

Completion

2022-06

Drugs

Indications